Merck & Co. logo
Merck & Co. MRK
$ 106.87 0.06%

Quarterly report 2025-Q3
added 11-05-2025

report update icon

Merck & Co. Gross Profit 2011-2025 | MRK

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Merck & Co.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - - 32.7 B 28.8 B 27.3 B 25.9 B 24.6 B 25.5 B 27.1 B 30.8 B 31.2 B

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
32.7 B 24.6 B 28.2 B

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
180 M - 2.43 % $ 254 M germanyGermany
Aclaris Therapeutics Aclaris Therapeutics
ACRS
172 K $ 3.0 -0.99 % $ 232 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
177 K $ 3.1 -0.64 % $ 7.46 B australiaAustralia
Midatech Pharma plc Midatech Pharma plc
MTP
-428 K - -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
-104 K $ 1.1 -3.51 % $ 6 M chinaChina
AIkido Pharma AIkido Pharma
AIKI
10 K - 1.93 % $ 17.4 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
319 M $ 211.15 1.04 % $ 5 B danmarkDanmark
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-523 K - -11.43 % $ 502 K usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
14 M - -4.8 % $ 255 M usaUSA
Athersys Athersys
ATHX
1.44 M - 3.77 % $ 22.4 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
500 - -9.72 % $ 5.89 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-32.3 K - 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
1.12 M - -15.15 % $ 60.3 M britainBritain
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
2.03 M $ 0.17 -18.84 % $ 370 M israelIsrael
Berkeley Lights Berkeley Lights
BLI
53.8 M - -7.31 % $ 87 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
39.2 M - -0.23 % $ 916 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
109 M $ 12.12 -1.86 % $ 798 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
374 M $ 26.86 -0.96 % $ 1.3 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
3.22 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Anika Therapeutics Anika Therapeutics
ANIK
103 M $ 9.53 -0.21 % $ 140 M usaUSA
Certara Certara
CERT
129 M $ 8.85 -0.45 % $ 1.42 B usaUSA
bluebird bio bluebird bio
BLUE
-4.03 M - - $ 546 M usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
37.7 M $ 4.95 4.2 % $ 116 M franceFrance
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
319 K - -6.81 % $ 3.04 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
1.27 M - 2.71 % $ 14 M usaUSA
Axon Enterprise Axon Enterprise
AXON
1.24 B $ 583.1 -0.13 % $ 44.2 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
90 K - - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
45.8 M $ 2.55 4.08 % $ 16 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
43.9 B $ 92.68 -0.24 % $ 96.9 B britainBritain
ChromaDex Corporation ChromaDex Corporation
CDXC
61.6 M - -0.88 % $ 598 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
119 M - -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
1.82 K - -5.38 % $ 6.06 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
5.48 M $ 25.93 -1.8 % $ 1.67 M usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
371 M $ 11.43 2.65 % $ 739 M usaUSA